In this interview, News-Medical talks to Dr. Klaus Lun and Chris Mason about the past, present and future of automation and digitalization in the life sciences laboratory and especially the impact this could have on next-generation sequencing and genomics.
Imlunestrant offers new hope for ER-positive HER2-negative breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients